PYC Therapeutics Limited (AU:PYC)
ASX:PYC
Top Page
PYC Therapeutics Limited
(Sydney:PYC)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$1.00
â–¼(-5.66% Downside)
Action:ReiteratedDate:11/25/25
PYC Therapeutics Limited's stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. While technical analysis indicates a positive trend, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. The lack of earnings call data and corporate events further limits the assessment.
Positive Factors
Low leverage
Low financial leverage provides durable financial flexibility for a cash-burning clinical-stage biotech. Minimal debt reduces fixed financing obligations, lowers bankruptcy risk, and preserves the ability to pursue R&D, partnerships or milestone-based financing over the next several months.
Negative Factors
Declining revenue & persistent losses
Sustained revenue declines and ongoing losses erode cash reserves and increase the probability of equity dilution or dependence on partner funding. For a clinical-stage biotech, this structurally limits the ability to self-fund trials and heightens execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Low financial leverage provides durable financial flexibility for a cash-burning clinical-stage biotech. Minimal debt reduces fixed financing obligations, lowers bankruptcy risk, and preserves the ability to pursue R&D, partnerships or milestone-based financing over the next several months.
Read all positive factors
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.05B
Dividend YieldN/A
Average Volume (3M)499.42K
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue GrowthN/A
EPS Growth-5.70%
CountryAU
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding983,260,440
10 Day Avg. Volume237,599
30 Day Avg. Volume499,416
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.84
Price to Sales (P/S)27.69
P/FCF Ratio-12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.65Price Target Upside244.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
PYC Therapeutics Limited Business Overview & Revenue Model
Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug progra...
How the Company Makes Money
null...
PYC Therapeutics Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.66M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 11.35M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -59.80M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -47.56M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 159.13M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 120.69M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.26M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 11.80M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 147.18M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -66.22M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -65.75M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -463.80K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.63M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
Negative
1.06
Price Trends
1.42
Negative
1.45
Negative
1.33
Negative
Market Momentum
-0.10
Positive
26.29
Positive
20.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Negative. The current price of 1.06 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.42, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 26.29 is Positive, neither overbought nor oversold. The STOCH value of 20.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PYC.
PYC Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$452.31M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
53 Neutral | AU$86.51M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.05B | -10.86 | -30.03% | ― | ― | -5.70% | |
47 Neutral | AU$1.14B | -5.54 | -54.37% | ― | ― | -29.93% | |
42 Neutral | AU$738.77M | -4.51 | 132.37% | ― | -80.08% | 59.91% | |
40 Underperform | AU$64.84M | -3.40 | -69.20% | ― | ― | -19.21% |
* Healthcare Sector Average
AU:PYC
PYC Therapeutics Limited
1.07
0.03
3.40%
AU:OPT
Opthea
0.60
0.00
0.00%
AU:CUV
Clinuvel Pharmaceuticals
9.01
-1.60
-15.06%
AU:IMM
Immutep Ltd
0.04
-0.21
-82.40%
AU:CU6
Clarity Pharmaceuticals Ltd.
3.05
1.51
98.05%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.33
-89.46%
PYC Therapeutics Limited Corporate Events
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
Mar 27, 2026
PYC Therapeutics has disclosed a change in the holdings of director Dr Rohan Hockings, who acquired 82,550 fully paid shares via an on-market purchase, increasing his direct stake from 213,360 to 295,910 shares. The transaction, valued at $99,883,...
PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
Mar 26, 2026
PYC Therapeutics is advancing its PYC-003 drug candidate, designed to address the underlying cause of Polycystic Kidney Disease, as part of its portfolio of RNA-based precision medicines for genetic disorders. The company plans to showcase progres...
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
Mar 23, 2026
PYC Therapeutics has highlighted progress in its clinical pipeline with new data and trial milestones for PYC-001, its investigational RNA therapy for Autosomal Dominant Optic Atrophy, a rare childhood blinding disease affecting about 1 in 35,000 ...
PYC Therapeutics CEO Increases Shareholding and Awaits Approval for New Options Grant
Mar 10, 2026
PYC Therapeutics has disclosed a change in director interests, with CEO Dr. Rohan Hockings increasing his direct holding by acquiring 80,010 ordinary shares through participation in a retail entitlement offer, bringing his total to 213,360 shares....
PYC Therapeutics Seeks ASX Quotation for Over 10.5 Million New Shares
Mar 9, 2026
PYC Therapeutics Limited has applied for quotation of 10,573,060 new fully paid ordinary shares on the Australian Securities Exchange, with an issue date of March 9, 2026. The additional securities, issued under a previously announced transaction,...
PYC Therapeutics Seeks ASX Quotation for Over 31 Million New Shares
Mar 5, 2026
PYC Therapeutics has applied for quotation on the ASX of 31,197,631 new fully paid ordinary shares, with an issue date of March 6, 2026. The securities arise from previously announced transactions and their quotation will expand the company’...
PYC Therapeutics appoints new joint company secretary to oversee ASX compliance
Mar 4, 2026
PYC Therapeutics has appointed Daniel Coletta as joint company secretary, effective immediately, alongside long-serving secretary Kevin Hart, who will retire at the end of March 2026 after nearly nine years in the role. The Board highlighted that ...
PYC Therapeutics Completes $47m Retail Entitlement Offer, Boosting Capital for RNA Programs
Mar 3, 2026
PYC Therapeutics Limited has completed the retail component of its pro rata accelerated non-renounceable entitlement offer, raising about $47 million at $1.50 per new share. The offer saw applications for roughly 31 million shares, including addit...
PYC Therapeutics Issues Cautious Q1 2026 Investor Update
Feb 23, 2026
PYC Therapeutics has released a Q1 2026 investor update outlining the status of its business and drug development pipeline, emphasizing that its candidates are investigational and not yet approved by regulators. The company stresses that the infor...
PYC Therapeutics Files Interim Results as RNA Pipeline Advances
Feb 23, 2026
PYC Therapeutics Limited has lodged its Appendix 4D and interim financial statements for the half-year ended 31 December 2025 with the ASX. The release signals continued progression of the company’s clinical-stage RNA therapeutic programs an...
PYC Therapeutics Seeks ASX Quotation for 354.8 Million New Shares
Feb 11, 2026
PYC Therapeutics Limited has applied for quotation on the ASX of 354,782,201 new fully paid ordinary shares, with an issue date of 12 February 2026. The securities are being admitted to quotation following a previously announced transaction, expan...
PYC Therapeutics Opens Retail Entitlement Offer to Fund RNA Therapy Pipeline
Feb 9, 2026
PYC Therapeutics has commenced the retail component of its previously announced 3-for-5 pro rata accelerated non-renounceable entitlement offer, confirming the dispatch of retail offer booklets and personalised entitlement and acceptance forms to ...
PYC Therapeutics launches major entitlement offer and placement to fund RNA therapy programs
Feb 8, 2026
PYC Therapeutics is launching a sizeable equity raising through a pro-rata accelerated non-renounceable entitlement offer, with eligible shareholders invited to subscribe for three new shares for every five held at A$1.50, to raise up to about A$5...
PYC Therapeutics Opens Retail Component of Entitlement Offer to Fund RNA Therapy Pipeline
Feb 8, 2026
PYC Therapeutics has opened the retail component of its previously announced 3-for-5 pro rata accelerated non-renounceable entitlement offer, giving eligible retail shareholders in Australia and New Zealand the opportunity to participate. The Reta...
PYC Therapeutics Sets Investor Webinar to Detail Capital Raise and Pipeline Progress
Feb 5, 2026
PYC Therapeutics will host an investor webinar on 24 February 2026, offering shareholders an update on its recent capital raise and providing a detailed overview of the progress and outlook for each of its four drug development programs. The sessi...
PYC Therapeutics Secures A$537m in Institutional Raising, Extends Cash Runway to 2030
Feb 4, 2026
PYC Therapeutics has closed the institutional placement and institutional component of its pro-rata accelerated non-renounceable entitlement offer, securing commitments of A$537 million at A$1.50 per new share from leading US specialist life scien...
PYC Therapeutics Launches Major Equity Raising via Entitlement Offer and Placement
Feb 2, 2026
PYC Therapeutics Limited has announced a proposed capital raising through an accelerated non-renounceable entitlement offer and a separate placement of ordinary fully paid shares, together amounting to a potential issue of 435,445,335 new shares. ...
PYC Therapeutics Launches Pro-Rata Entitlement Offer With Limited Control Impact
Feb 2, 2026
PYC Therapeutics Limited has launched a pro-rata non-renounceable entitlement offer, allowing eligible shareholders in Australia, New Zealand and certain other jurisdictions to subscribe for three new fully paid ordinary shares for every five shar...
PYC Therapeutics Launches Equity Raising via Entitlement Offer and Institutional Placement
Feb 2, 2026
PYC Therapeutics has launched an equity raising initiative comprising an accelerated non-renounceable entitlement offer to eligible institutional and retail shareholders and a share placement to institutional investors, all involving new fully pai...
PYC Therapeutics to Raise Up to A$653m to Advance Four Genetic Disease Drugs
Feb 2, 2026
PYC Therapeutics has launched a major equity raising of up to A$653 million to advance four high-potential genetic disease drug candidates through key human efficacy milestones. The capital will be raised via a A$128 million placement to leading U...
PYC Therapeutics Requests Trading Halt Ahead of Capital Raising
Feb 1, 2026
PYC Therapeutics has requested a trading halt in its securities on the ASX as it prepares a significant capital raising initiative. The halt will remain in place until either the completion announcement of the institutional component of a pro rata...
PYC Therapeutics Advances RNA Drug Pipeline With Key Q4 2025 Clinical Milestones
Jan 22, 2026
In its fourth-quarter 2025 update, PYC Therapeutics reported continued progress across all four of its pipeline programs, highlighting key clinical milestones and positioning the company for important safety and efficacy read-outs over the next tw...
PYC Therapeutics Grants Growth-Tied Option Package to Managing Director
Jan 13, 2026
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1.5 million unlisted options to managing director Dr Rohan Hockings under its Long Term Incentive Plan, with a four-year expiry, growth-oriented exercise price of $2.5...
PYC Therapeutics Corrects Option Strike Price in Updated Appendix 3G
Jan 13, 2026
PYC Therapeutics Limited has issued an updated notification to the ASX correcting a typographical error in a previously lodged Appendix 3G relating to unquoted equity securities. The company clarified that the option strike price for the relevant ...
PYC Therapeutics Updates Corporate Presentation for JP Morgan Healthcare Conference
Jan 12, 2026
PYC Therapeutics has released an updated corporate presentation timed with its participation at the 44th annual JP Morgan Healthcare Conference in San Francisco, underscoring its ongoing efforts to position itself among leading players in the RNA ...
PYC Therapeutics Offers 1 Million Director Options Under Long-Term Incentive Plan
Jan 9, 2026
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1,000,000 unlisted options to director Professor Ian Constable under its Long Term Incentive Plan, matching the vesting conditions and A$1.80 strike price of options p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.